Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Cartalax
Also known as: Ala-Glu-Asp, AED
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator program, designed to support cartilage and musculoskeletal tissue. It is proposed to promote chondrocyte function and normalize cartilage metabolism. Evidence is extremely limited, consisting of a small number of in vitro studies and Russian observational reports.
Risk Level
Low RiskDifficulty
Intermediate| Molecular Formula | C12H19N3O8 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in chondrocytes and cartilage tissue, promoting normal extracellular matrix synthesis and reducing age-related cartilage degradation. In vitro studies suggest modulation of collagen and proteoglycan synthesis in cartilage cells.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 15-30 days. Some protocols combine with other musculoskeletal bioregulators. Repeat courses recommended every 3-6 months. No injectable formulation commonly used.
Side Effects & Risks
No adverse effects documented. The tripeptide is rapidly metabolized, which theoretically limits risk. No controlled human safety studies exist. Joint-health claims are not supported by adequate clinical evidence.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.